Edition:
United Kingdom

Biomerica Inc (BMRA.OQ)

BMRA.OQ on NASDAQ Stock Exchange Capital Market

2.42USD
5:24pm BST
Change (% chg)

$0.02 (+0.83%)
Prev Close
$2.40
Open
$2.42
Day's High
$2.48
Day's Low
$2.40
Volume
3,052
Avg. Vol
5,893
52-wk High
$4.33
52-wk Low
$1.60

Latest Key Developments (Source: Significant Developments)

Biomerica Announces Updates For H. Pylori Clinical Studies
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Biomerica Inc ::BIOMERICA ANNOUNCES UPDATES FOR H. PYLORI CLINICAL STUDIES.BIOMERICA - BASED ON RECENT DISCUSSIONS WITH FDA, CO NEEDS LESS THAN 40 CLINICAL TRIAL PATIENT SAMPLES IN ADDITION TO 210 SAMPLES ALREADY COLLECTED.BIOMERICA - FINAL CLINICAL PATIENT SAMPLES EXPECTED TO BE COLLECTED OVER NEXT FEW MONTHS, AFTER WHICH CO TO COMPLETE REMAINING STUDIES, PREPARE FDA SUBMISSION.  Full Article

Biomerica Reports Q2 Loss Per Share Of $0.05
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Biomerica Inc ::BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.05.Q2 SALES $1.501 MILLION VERSUS $1.614 MILLION.  Full Article

Medline And Biomerica Sign Agreement For Distribution Of Biomerica's Colorectal Screening Test
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Biomerica Inc ::MEDLINE AND BIOMERICA SIGN AGREEMENT FOR DISTRIBUTION OF BIOMERICA’S COLORECTAL SCREENING TEST TO HELP IDENTIFY AN EARLY WARNING SIGN OF COLORECTAL CANCER.BIOMERICA INC - 3-YEAR AGREEMENT WITH MEDLINE INDUSTRIES FOR DISTRIBUTION OF EZ DETECT COLORECTAL DISEASE SCREENING TEST.  Full Article

Biomerica Q2 Loss Per Share $0.03
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Biomerica Inc ::BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER.Q2 LOSS PER SHARE $0.03.Q2 SALES ROSE 12.7 PERCENT TO $1.614 MILLION.  Full Article

China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Biomerica Inc ::CHINA FOOD AND DRUG ADMINISTRATION (CFDA) APPROVES BIOMERICA COLORECTAL SCREENING TEST TO HELP IDENTIFY THE EARLY WARNING SIGNS OF COLORECTAL CANCER.  Full Article

Biomerica extends license agreement with Celtis Pharm
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Biomerica Inc ::Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019.Biomerica Inc - has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea​.Biomerica - ‍term of exclusivity agreement is five years with an additional two years for telcon to receive Korean FDA clearance​.Biomerica - agreement may be cancelled if co has not obtained final clearance for sale of products in U.S. from FDA on or before December 31, 2019​.  Full Article

Biomerica Inc Q1 ‍net sales $1.4 million
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Biomerica Inc :Net sales of $1.4 million for three months ending August 31, 2017, an increase of 2.4%​.Net loss for three months ended August 31, 2017 was $207,059 compared to a net loss of $55,417 during same period in fiscal 2017​.  Full Article